CYTOF — Altamira Therapeutics Ltd.

OTC · Health Care · Pharmaceuticals · CIK 1601936 ·
Last close
$0.05
Market Cap
$291.8K
52W High
$0.12
52W Low
$0.05
ADV30
3,780
Next earnings
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II clinical trial for the intranasal treatment of vertigo. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2025 7,130,183 3,755 3,056,371
Dec 2024 8,652,136 998,624 2,087,030

Balance + Analyst (yfinance extras)

Retained Earnings
$-4,041,241
Inventory
$0
Receivables
$213,389
ST Investments
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 0 -6,921,740 -8,457,748 8,652,136 2,087,030 -6,113,547
Dec 2023 0 -6,601,112 -4,306,260 9,143,504 1,468,261 -12,811,427
Dec 2022 0 -18,862,743 -27,778,443 6,813,063 15,801,076 -9,092,388

Peers — same industry

TickerNameMarket CapLastDaily %
VGLS SB Technology Holdings, Inc. $316.4K $0.30
PTPI Petros Pharmaceuticals, Inc. $258.5K $0.01
BPTH BIO-PATH HOLDINGS, INC. $345.7K $0.04
CNBX CNBX Pharmaceuticals Inc. $245.2K $0.00
IOBTQ IO Biotech, Inc. $215.8K $0.00

News headlines (Yahoo Finance, 1h cache)

Altamira Therapeutics Announces Publication Highlighting Potential of RNA Nanoparticles for Disease-Modifying Treatment of Osteoarthritis
2026-04-13 13:00 · Yahoo
Altamira Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
2026-03-31 13:00 · Yahoo
Altamira Therapeutics Announces Release Date for 2025 Annual Report and Financial Statements
2026-03-24 13:00 · Yahoo
Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Bentrio Nasal Spray
2026-02-13 14:00 · Yahoo
Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit
2026-01-23 14:00 · Yahoo
Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China
2025-12-19 14:00 · Yahoo
Altamira Therapeutics Announces Certification of Bentrio Nasal Spray under Medical Device Regulation
2025-11-20 14:00 · Yahoo
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules
2025-11-03 14:00 · Yahoo
Altamira Therapeutics Provides Business Update and First Half 2025 Financial Results
2025-08-29 11:30 · Yahoo
Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025
2025-08-26 20:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.